Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
This article was originally published in PharmAsia News
Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.
You may also be interested in...
Sangamo used 2013 to progress its pipeline, to raise money and to acquire a company. The momentum carried into the first quarter of 2014 with the Biogen partnership and a jump in share price that suggested that investors finally may have bought into the gene therapy company’s unique story.
The G8 dementia summit saw politicians, health stakeholders and financiers agree to target Alzheimer’s disease together, but a silver bullet may be years away.
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.